Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H19NOS |
Molecular Weight | 297.415 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNCC[C@@H](OC1=C2C=CC=CC2=CC=C1)C3=CC=CS3
InChI
InChIKey=ZEUITGRIYCTCEM-QGZVFWFLSA-N
InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m1/s1
Molecular Formula | C18H19NOS |
Molecular Weight | 297.415 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/26646348
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26646348
R-Duloxetine is an enantiomer of the antidepressant S-duloxetine. R-Duloxetine was shown was highly effective against postoperative pain, which could be potential new analgesics. R-Duloxetine could show its effect via the blocking of the neuronal Na⁺ channels.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: neuronal sodium channels Sources: https://www.ncbi.nlm.nih.gov/pubmed/26646348 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26646348 |
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
A chemoenzymatic dynamic kinetic resolution approach to enantiomerically pure (R)- and (S)-duloxetine. | 2011 May 20 |
|
Investigation on the enantioseparation of duloxetine by capillary electrophoresis, NMR, and mass spectrometry. | 2014 Oct |
|
Development of chiral methodologies by capillary electrophoresis with ultraviolet and mass spectrometry detection for duloxetine analysis in pharmaceutical formulations. | 2014 Oct 10 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26646348
rat incision: Ipsilateral SC injections (2 mg/0.4 mL) of R-duloxetine reduced both postoperative allodynia and hyperalgesia by approximately 89% to 99% in the area under the curve of skin responses next to incision over 5 days. Systemic intraperitoneal injections at a higher dosage (10 mg) had smaller analgesic effects (reduced by approximately 53%-69%), whereas contralateral SC injections (10 mg) were ineffective.
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:17:52 GMT 2023
by
admin
on
Sat Dec 16 05:17:52 GMT 2023
|
Record UNII |
TK9VOT90JQ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
116539-60-7
Created by
admin on Sat Dec 16 05:17:53 GMT 2023 , Edited by admin on Sat Dec 16 05:17:53 GMT 2023
|
PRIMARY | |||
|
10334821
Created by
admin on Sat Dec 16 05:17:53 GMT 2023 , Edited by admin on Sat Dec 16 05:17:53 GMT 2023
|
PRIMARY | |||
|
DTXSID40151424
Created by
admin on Sat Dec 16 05:17:53 GMT 2023 , Edited by admin on Sat Dec 16 05:17:53 GMT 2023
|
PRIMARY | |||
|
TK9VOT90JQ
Created by
admin on Sat Dec 16 05:17:53 GMT 2023 , Edited by admin on Sat Dec 16 05:17:53 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|